De-Risking Drug Discovery - Molecular Med Tri-Conference

Cambridge Healthtech Institute's Inaugural De-Risking Drug Discovery conference at the 2012 Molecular Med Tri-Con will bring scientists from academia, industry and government together to present and discuss the latest strategies, methods and technologies available to reduce the risk associated with pharmaceutical candidates, both pre-clinical and clinical. De-risking strategies have evolved to provide evaluation of risk, assignment of risk to better allocate resources (personnel, funds, time) and lower the overall attrition rates for pharmaceutical products, but this is not enough. Meet experts from across pharma and biotech, in both small and large molecules, as they begin to break down the steps, technologies and business approaches you can use to de-risk. Is it better to bring in de-risked lead compounds or install the process in an organization? What are the different business model approaches and how have they been effective? Learn how to utilize the expertise within contract research organizations. Explore drug repositioning and repurposing as opportunities for failed or high risk projects. Participate in discussions on the importance of target vs. molecule de-risking and why different strategies might be needed. Novel technologies and novel applications of current technologies can be used to improve risk or to establish risk values early. Listen to experts from drug discovery, drug safety and toxicology, and translational medicine as they describe their methodologies and experiences. Meet with industry and academic experts during networking events to share your own experiences and expertise.

• Category

  Science & Technology